SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer
نویسندگان
چکیده
منابع مشابه
Systemic Therapy for Invasive Bladder Cancer.
BACKGROUND: Bladder cancer is one of the most common malignancies in Western society. In the United States, approximately 10,000 of these patients present with invasive disease, and more progress from superficial bladder cancer. METHODS: The authors review the literature on systemic treatment for both localized and metastatic bladder cancer, and they include their experience in defining approac...
متن کاملMicroRNAs as biomarkers associated with bladder cancer
Bladder cancer is the fifth most common cancer with significant morbidity and mortality. Recently, numerous studies demonstrated that microRNAs are emerging as diagnostic biomarkers for bladder cancer. Specific miRNA profiles have been identified for several samples from patients with bladder cancer. MicroRNAs are noncoding RNA molecules of approximately 23 nucleotides that play important roles...
متن کاملSystemic chemotherapy in inoperable or metastatic bladder cancer.
Urothelial cancer is a common malignancy. The management of patients with recurrent disease after cystectomy or initially metastatic or unresectable disease represents a therapeutic challenge. Systemic chemotherapy prolongs survival but long-term survival remains infrequent. During recent years there has been improvement due to the use of novel chemotherapeutic agents, mainly gemcitabine and th...
متن کاملSystemic Therapy for Invasive Bladder Cancer: The Value Proposition
The report from Yin et al. in this issue of The Oncologist is an important reminder of the utility of neoadjuvant cisplatinbased chemotherapy for invasive, clinically nonmetastatic bladder cancer [1]. In their updated analysis, these investigators suggest that the hazard ratio from this treatment strategy has improved to 0.87, from approximately 0.93; the analysis now includesmore than 3,000 ca...
متن کاملSystemic therapy for bladder cancer - a medical oncologist's perspective.
Advanced bladder cancer, both muscle-invasive localized disease and metastatic disease, is managed with systemic chemotherapy. Cisplatin-based multi-agent chemotherapy remains the cornerstone for systemic therapy. MVAC (methotrexate-vinblastine-doxorubicin-cisplatin) has been most rigorously studied, both neoadjuvantly and for palliation of metastatic disease. For metastatic disease, cisplatin-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Urology
سال: 2018
ISSN: 0724-4983,1433-8726
DOI: 10.1007/s00345-018-2486-1